What is Oxigrex?
Oxigrex is an anticonvulsant, or antiepileptic drug. It works by decreasing nerve impulses that cause seizures.
Oxigrex is used either alone or with other medicines to treat partial seizures.
The Oxigrex brand of Oxigrex is used as a single medicine in adults and children who are at least 4 years old. Oxigrex is used with other medicines in adults and children who are at least 2 years old.
The Oxigrex brand of Oxigrex is used with other medicines in adults and children who are at least 6 years old.
Oxigrex may also be used for purposes not listed in this medication guide.
Oxigrex indications
Oxigrex is indicated in adults and in children aged 1 month and above for the treatment of partial seizures (which include the seizure subtypes of simple, complex and partial seizures evolving to secondarily generalized seizures) and generalized tonic-clonic seizures.
Oxigrex is indicated as a first-line antiepileptic drug for use as monotherapy or adjunctive therapy.
Oxigrex can replace other antiepileptic drugs when current therapy provides insufficient seizure control.
How should I use Oxigrex?
Use Oxigrex suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Oxigrex suspension comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Oxigrex suspension refilled.
- Take Oxigrex suspension by mouth with or without food.
- Shake well before each use.
- Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- Oxigrex suspension may be mixed in a small glass of water just before taking/giving it or it may be swallowed directly from the syringe.
- After each use, close the bottle and rinse the syringe with warm water. Allow it to dry thoroughly.
- Taking Oxigrex suspension at the same times each day will help you remember to take it.
- Continue to take Oxigrex suspension even if you feel well. Do not miss any doses. Oxigrex suspension works best when there is a constant level of it in your body.
- If Oxigrex suspension is stopped, it should be done gradually as directed by your doctor. The risk of seizures may be increased if Oxigrex suspension is suddenly stopped.
- If you miss a dose of Oxigrex suspension, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Oxigrex suspension.
Uses of Oxigrex in details
Use: Labeled Indications
Focal (partial) onset seizures:
Immediate-release: Monotherapy or adjunctive therapy in the treatment of focal (partial) onset seizures in adults, as monotherapy in the treatment of focal (partial) onset seizures in children ≥4 years of age with epilepsy, and as adjunctive therapy in children ≥2 years of age with focal (partial) onset seizures.
Extended-release: Treatment of focal (partial) onset seizures in adults and in children ≥6 years of age.
Off Label Uses
Neuropathic pain
Data from a multicenter, double-blind, placebo-controlled study supports the use of Oxigrex monotherapy in the treatment of neuropathic pain of diabetic origin.
Oxigrex description
Each Oxigrex film-coated tablet contains 300 mg or 600 mg Oxigrex.
Each 1 mL of Oxigrex oral suspension contains 60 mg Oxigrex.
Excipients/Inactive Ingredients: Tablet Core: Silica, colloidal anhydrous; cellulose, microcrystalline; hypromellose; crospovidone; magnesium stearate.
Tablet Coating: Hypromellose, talc, titanium dioxide (E171).
150 mg Tablet Coating only: Macrogol 4000; iron oxide, yellow (E172); iron oxide red (E172), iron oxide black (E172).
300 mg Tablet Coating only: Macrogol 8000; iron oxide, yellow (E172).
600 mg Tablet Coating only: Macrogol 4000; iron oxide red (E172); iron oxide black (E172).
Oral Suspension:
Propyl parahydroxybenzoate (E216), saccharin sodium, sorbic acid (E200), macrogol stearate 400, methyl parahydroxybenzoate (E218), yellow-plum-lemon flavour, ascorbic acid (E300), dispersible cellulose, propylene glycol, sorbitol 70% (non-crystallising), purified water. Ethanol is a component of the flavor.Oxigrex dosage
Oxigrex Dosage
Generic name: Oxigrex 150mg
Dosage form: tablet, film coated; oral suspension
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
All dosing should be given in a twice-a-day regimen. Oxigrex oral suspension and Oxigrex film-coated tablets may be interchanged at equal doses.
Oxigrex should be kept out of the reach and sight of children.
Before using Oxigrex oral suspension, shake the bottle well and prepare the dose immediately afterwards. The prescribed amount of oral suspension should be withdrawn from the bottle using the oral dosing syringe supplied. Oxigrex oral suspension can be mixed in a small glass of water just prior to administration or, alternatively, may be swallowed directly from the syringe. After each use, close the bottle and rinse the syringe with warm water and allow it to dry thoroughly.
Oxigrex can be taken with or without food.
2.1 Adjunctive Therapy for Adults
Treatment with Oxigrex should be initiated with a dose of 600 mg/day, given in a twice-a-day regimen. If clinically indicated, the dose may be increased by a maximum of 600 mg/day at approximately weekly intervals; the recommended daily dose is 1200 mg/day. Daily doses above 1200 mg/day show somewhat greater effectiveness in controlled trials, but most patients were not able to tolerate the 2400 mg/day dose, primarily because of CNS effects. It is recommended that the patient be observed closely and plasma levels of the concomitant AEDs be monitored during the period of Oxigrex titration, as these plasma levels may be altered, especially at Oxigrex doses greater than 1200 mg/day.
2.2 Conversion to Monotherapy for Adults
Patients receiving concomitant AEDs may be converted to monotherapy by initiating treatment with Oxigrex at 600 mg/day (given in a twice-a-day regimen) while simultaneously initiating the reduction of the dose of the concomitant AEDs. The concomitant AEDs should be completely withdrawn over 3-6 weeks, while the maximum dose of Oxigrex should be reached in about 2-4 weeks. Oxigrex may be increased as clinically indicated by a maximum increment of 600 mg/day at approximately weekly intervals to achieve the recommended daily dose of 2400 mg/day. A daily dose of 1200 mg/day has been shown in one study to be effective in patients in whom monotherapy has been initiated with Oxigrex. Patients should be observed closely during this transition phase.
2.3 Initiation of Monotherapy for Adults
Patients not currently being treated with AEDs may have monotherapy initiated with Oxigrex. In these patients, Oxigrex should be initiated at a dose of 600 mg/day (given in a twice-a-day regimen); the dose should be increased by 300 mg/day every third day to a dose of 1200 mg/day. Controlled trials in these patients examined the effectiveness of a 1200 mg/day dose; a dose of 2400 mg/day has been shown to be effective in patients converted from other AEDs to Oxigrex monotherapy.
2.4 Adjunctive Therapy for Pediatric Patients (Aged 2-16 Years)
In pediatric patients aged 4-16 years, treatment should be initiated at a daily dose of 8-10 mg/kg generally not to exceed 600 mg/day, given in a twice-a-day regimen. The target maintenance dose of Oxigrex should be achieved over two weeks, and is dependent upon patient weight, according to the following chart:
20-29 kg - 900 mg/day
29.1-39 kg - 1200 mg/day
>39 kg - 1800 mg/day
In the clinical trial, in which the intention was to reach these target doses, the median daily dose was 31 mg/kg with a range of 6-51 mg/kg.
In pediatric patients aged 2-<4 years, treatment should also be initiated at a daily dose of 8-10 mg/kg generally not to exceed 600 mg/day, given in a twice-a-day regimen. For patients under 20 kg, a starting dose of 16-20 mg/kg may be considered. The maximum maintenance dose of Oxigrex should be achieved over 2-4 weeks and should not exceed 60 mg/kg/day in a twice-a-day regimen.
In the clinical trial in pediatric patients (2 to 4 years of age) in which the intention was to reach the target dose of 60 mg/kg/day, 50% of patients reached a final dose of at least 55 mg/kg/day.
Under adjunctive therapy (with and without enzyme-inducing AEDs), when normalized by body weight, apparent clearance (L/hr/kg) decreased when age increased such that children 2 to <4 years of age may require up to twice the Oxigrex dose per body weight compared to adults; and children 4 to ≤12 years of age may require a 50% higher Oxigrex dose per body weight compared to adults.
2.5 Conversion to Monotherapy for Pediatric Patients (Aged 4-16 Years)
Patients receiving concomitant antiepileptic drugs may be converted to monotherapy by initiating treatment with Oxigrex at approximately 8-10 mg/kg/day given in a twice-a-day regimen, while simultaneously initiating the reduction of the dose of the concomitant antiepileptic drugs. The concomitant antiepileptic drugs can be completely withdrawn over 3-6 weeks while Oxigrex may be increased as clinically indicated by a maximum increment of 10 mg/kg/day at approximately weekly intervals to achieve the recommended daily dose. Patients should be observed closely during this transition phase.
The recommended total daily dose of Oxigrex is shown in the table below.
2.6 Initiation of Monotherapy for Pediatric Patients (Aged 4-16 Years)
Patients not currently being treated with antiepileptic drugs may have monotherapy initiated with Oxigrex. In these patients, Oxigrex should be initiated at a dose of 8-10 mg/kg/day given in a twice-a-day regimen. The dose should be increased by 5 mg/kg/day every third day to the recommended daily dose shown in the table below.
From | To | |
Weight in kg | Dose (mg/day) | Dose (mg/day) |
20 | 600 | 900 |
25 | 900 | 1200 |
30 | 900 | 1200 |
35 | 900 | 1500 |
40 | 900 | 1500 |
45 | 1200 | 1500 |
50 | 1200 | 1800 |
55 | 1200 | 1800 |
60 | 1200 | 2100 |
65 | 1200 | 2100 |
70 | 1500 | 2100 |
2.7 Patients with Hepatic Impairment
In general, dose adjustments are not required in patients with mild-to-moderate hepatic impairment
2.8 Patients with Renal Impairment
In patients with impaired renal function (creatinine clearance <30 mL/min) Oxigrex therapy should be initiated at one-half the usual starting dose (300 mg/day) and increased slowly to achieve the desired clinical response
More about Oxigrex (Oxigrex)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 64 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Oxigrex
- Oxigrex suspension
- Oxigrex (Advanced Reading)
- Other brands: Oxigrex
Professional resources
- Oxigrex (AHFS Monograph)
- Oxigrex (FDA)
Related treatment guides
- Epilepsy
- Seizures
Oxigrex interactions
See also:
What other drugs will affect Oxigrex?
Oxigrex and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5).
In addition, several AEDs that are cytochrome P450 inducers can decrease plasma concentrations of Oxigrex and MHD.
These interactions have implications when Oxigrex® is used with other AEDs or hormonal contraceptives.
Other Antiepileptic Drugs
Potential interactions between immediate-release Oxigrex and other AEDs were assessed in clinical studies. Oxigrex®would be expected to have the same effects on coadministered AEDs as immediate-release Oxigrex.
Table 5: AED Drug Interactions with Oxigrex
AED Coadministered (daily dose) | IR- Oxigrex (daily dose) | Influence of IR-Oxigrex on AED Concentration Mean Change [90% Confidence Interval] | Influence of AED on MHD Concentration (Mean Change, 90% Confidence Interval) | Recommendation |
Carbamazepine (400 - 2000 mg) | 900 mg | ncMean increase in adults at high doses of immediate-release Oxigrex |
Hormonal Contraceptives
Coadministration of immediate-release Oxigrex with an oral contraceptive decreased the plasma concentrations of two components of hormonal contraceptives, ethinylestradiol and levonorgestrel. Therefore, concurrent use of Oxigrex® with these hormonal contraceptives and other oral or implant contraceptives may render these contraceptives less effective. Additional non-hormonal forms of contraception are recommended.
Drug Abuse And Dependence
Abuse
The abuse potential of Oxigrex® has not been evaluated in human studies. Oxigrex® is not habit forming, and is not expected to encourage abuse.
Dependence
Intragastric injections of Oxigrex to four cynomolgus monkeys demonstrated no signs of physical dependence as measured by the desire to self-administer Oxigrex by lever pressing activity.
Oxigrex side effects
See also:
What are the possible side effects of Oxigrex?
The following adverse reactions are described in other sections of the labeling:
- Hyponatremia
- Anaphylactic Reactions and Angioedema
- Hypersensitivity Reactions in Patients with Hypersensitivity to Carbamazepine
- Serious Dermatological Reactions
- Suicidal Behavior and Ideation
- Withdrawal of AEDs
- Multi-Organ Hypersensitivity
- Hematologic Reactions
- Risk of Seizures in the Pregnant Patient
- Laboratory Tests
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety data presented below are from 384 patients with partial epilepsy who received Oxigrex® (366 adults and 18 children) with concomitant AEDs.
In addition, safety data presented below are from a total of 2,288 patients with seizure disorders treated with immediate-release Oxigrex; 1,832 were adults and 456 were children.
Most Common Adverse Reactions Reported by Adult Patients Receiving Concomitant AEDs in Oxigrex® Clinical Studies
Table 3 lists adverse reactions that occurred in at least 2% of adult patients with epilepsy treated with Oxigrex® or placebo and concomitant AEDs and that were numerically more common in the patients treated with any dose of Oxigrex® than in patients receiving placebo.
The overall incidence of adverse reactions appeared to be dose related, particularly during the titration period. The most commonly observed ( ≥ 5%) adverse reactions seen in association with Oxigrex® and more frequent than in placebo-treated patients were: dizziness, somnolence, headache, balance disorder, tremor, vomiting, diplopia, and asthenia.
Table 3: Adverse Reaction Incidence in a Controlled Clinical Study of Oxigrex® with Concomitant AEDs in Adults*
Oxigrex® 2400 mg/day N=123 % | Oxigrex® 1200 mg/day N=122 % | Placebo N=121 % | |
Any System / Any Term | 69 | 57 | 55 |
Nervous System Disorders | |||
Dizziness | 41 | 20 | 15 |
Somnolence | 14 | 12 | 9 |
Headache | 15 | 8 | 7 |
Balance Disorder | 7 | 5 | 5 |
Tremor | 1 | 5 | 2 |
Nystagmus | 3 | 3 | 1 |
Ataxia | 1 | 3 | 1 |
Gastrointestinal Disorders | |||
Vomiting | 15 | 6 | 9 |
Abdominal Pain Upper | 0 | 3 | 1 |
Dyspepsia | 0 | 3 | 1 |
Gastritis | 0 | 3 | 2 |
Eye Disorders | |||
Diplopia | 13 | 10 | 4 |
Vision Blurred | 1 | 4 | 3 |
Visual Impairment | 1 | 3 | 0 |
General Disorders And Administration Site Conditions | |||
Asthenia | 7 | 3 | 1 |
Fatigue | 3 | 6 | 1 |
Gait Disturbance | 0 | 3 | 1 |
Drug Intolerance | 2 | 0 | 0 |
Infections And Infestations | |||
Nasopharyngitis | 0 | 3 | 0 |
Sinusitis | 0 | 3 | 2 |
* Reported by ≥ 2% of Patients Treated with Oxigrex® and Numerically More Frequent than in the Placebo Group |
Adverse Reactions Associated with Discontinuation of Oxigrex® Treatment
Approximately 23.3% of the 366 adult patients receiving Oxigrex® in clinical studies discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation of Oxigrex® (reported by ≥ 2%) were: dizziness (9.8%), vomiting (5.3%), nausea (3.7%), diplopia (3.2%), and somnolence (2.4%).
Adjunctive Therapy with Oxigrex® in Pediatric Patients 4 to 16 Years Old Previously Treated with other AEDs
In a pharmacokinetic study in 18 children (age 4-16 years) with partial seizures treated with different doses of Oxigrex®, the observed adverse reactions seen in association with Oxigrex® were similar to those seen in adults.
Most Common Adverse Reactions in Immediate-Release Oxigrex Controlled Clinical Studies
Controlled Clinical Studies of Adjunctive Therapy with Immediate-Release Oxigrex in Adults Previously Treated with other AEDs: Table 4 lists adverse reactions that occurred in at least 2% of adult patients with epilepsy treated with immediate-release Oxigrex or placebo with concomitant AEDs and that were numerically more common in the patients treated with any dose of immediate-release Oxigrex than in placebo. As immediate-release Oxigrex and Oxigrex® were not examined in the same trial, adverse event frequencies cannot be directly compared between the two formulations.
Table 4: Adverse Reaction Incidence in a Controlled Clinical Study of Immediate Release Oxigrex with Concomitant AEDs in Adults*
Immediate-Release Oxigrex Dosage (mg/day) | Placebo N = 166 % | |||
OXC 600 N = 163 % | OXC 1200 N = 171 % | OXC 2400 N = 126 % | ||
Body as a Whole | ||||
Fatigue | 15 | 12 | 15 | 7 |
Asthenia | 6 | 3 | 6 | 5 |
Edema Legs | 2 | 1 | 2 | 1 |
Weight Increase | 1 | 2 | 2 | 1 |
Feeling Abnormal | 0 | 1 | 2 | 0 |
Cardiovascular System | ||||
Hypotension | 0 | 1 | 2 | 0 |
Digestive System | ||||
Nausea | 15 | 25 | 29 | 10 |
Vomiting | 13 | 25 | 36 | 5 |
Pain Abdominal | 10 | 13 | 11 | 5 |
Diarrhea | 5 | 6 | 7 | 6 |
Dyspepsia | 5 | 5 | 6 | 2 |
Constipation | 2 | 2 | 6 | 4 |
Gastritis | 2 | 1 | 2 | 1 |
Metabolic and Nutritional Disorders | ||||
Hyponatremia | 3 | 1 | 2 | 1 |
Musculoskeletal System | ||||
Muscle Weakness | 1 | 2 | 2 | 0 |
Sprains and Strains | 0 | 2 | 2 | 1 |
Nervous System | ||||
Headache | 32 | 28 | 26 | 23 |
Dizziness | 36 | 32 | 49 | 13 |
Somnolence | 20 | 28 | 36 | 12 |
Ataxia | 9 | 17 | 31 | 5 |
Nystagmus | 7 | 20 | 26 | 5 |
Gait Abnormal | 5 | 10 | 17 | 1 |
Insomnia | 4 | 2 | 3 | 1 |
Tremor | 3 | 8 | 16 | 5 |
Nervousness | 2 | 4 | 2 | 1 |
Agitation | 1 | 1 | 2 | 1 |
Coordination Abnormal | 1 | 3 | 2 | 1 |
EEG Abnormal | 0 | 0 | 2 | 0 |
Speech Disorder | 1 | 1 | 3 | 0 |
Confusion | 1 | 1 | 2 | 1 |
Cranial Injury NOS | 1 | 0 | 2 | 1 |
Dysmetria | 1 | 2 | 3 | 0 |
Thinking Abnormal | 0 | 2 | 4 | 0 |
Respiratory System | ||||
Rhinitis | 2 | 4 | 5 | 4 |
Skin and Appendages | ||||
Acne | 1 | 2 | 2 | 0 |
Special Senses | ||||
Diplopia | 14 | 30 | 40 | 5 |
Vertigo | 6 | 12 | 15 | 2 |
Vision Abnormal | 6 | 14 | 13 | 4 |
Accommodation Abnormal | 0 | 0 | 2 | 0 |
* Events in at Least 2% of Patients Treated with 2400mg/day of Immediate-Release Oxigrex and Numerically More Frequent than in the Placebo Group |
Other Reactions Observed in Association with the Administration of Immediate-Release Oxigrex
In the paragraphs that follow, the adverse reactions, other than those in the preceding tables or text, that occurred in a total of 565 children and 1,574 adults exposed to immediate-release Oxigrex and that are reasonably likely to be related to drug use are presented. Events common in the population, events reflecting chronic illness and events likely to reflect concomitant illness are omitted particularly if minor. They are listed in order of decreasing frequency. Because the reports cite reactions observed in open label and uncontrolled trials, the role of immediate-release Oxigrex in their causation cannot be reliably determined.
Body as a Whole: fever, malaise, pain chest precordial, rigors, weight decrease.
Cardiovascular System: bradycardia, cardiac failure, cerebral hemorrhage, hypertension, hypotension postural, palpitation, syncope, tachycardia.
Digestive System: appetite increased, blood in stool, cholelithiasis, colitis, duodenal ulcer, dysphagia, enteritis, eructation, esophagitis, flatulence, gastric ulcer, gingival bleeding, gum hyperplasia, hematemesis, hemorrhage rectum, hemorrhoids, hiccup, mouth dry, pain biliary, pain right hypochondrium, retching, sialoadenitis, stomatitis, stomatitis ulcerative.
Hematologic and Lymphatic System: thrombocytopenia.
Laboratory Abnormality: gamma-GT increased, hyperglycemia, hypocalcemia, hypoglycemia, hypokalemia, liver enzymes elevated, serum transaminase increased.
Musculoskeletal System: hypertonia muscle.
Nervous System: aggressive reaction, amnesia, anguish, anxiety, apathy, aphasia, aura, convulsions aggravated, delirium, delusion, depressed level of consciousness, dysphonia, dystonia, emotional lability, euphoria, extrapyramidal disorder, feeling drunk, hemiplegia, hyperkinesia, hyperreflexia, hypoesthesia, hypokinesia, hyporeflexia, hypotonia, hysteria, libido decreased, libido increased, manic reaction, migraine, muscle contractions involuntary, nervousness, neuralgia, oculogyric crisis, panic disorder, paralysis, paroniria, personality disorder, psychosis, ptosis, stupor, tetany.
Respiratory System: asthma, bronchitis, coughing, dyspnea, epistaxis, laryngismus, pleurisy.
Skin and Appendages: acne, alopecia, angioedema, bruising, dermatitis contact, eczema, facial rash, flushing, folliculitis, heat rash, hot flushes, photosensitivity reaction, pruritus genital, psoriasis, purpura, rash erythematous, rash maculopapular, vitiligo, urticaria.
Special Senses: accommodation abnormal, cataract, conjunctival hemorrhage, edema eye, hemianopia, mydriasis, otitis externa, photophobia, scotoma, taste perversion, tinnitus, xerophthalmia.
Urogenital and Reproductive System: dysuria, hematuria, intermenstrual bleeding, leukorrhea, menorrhagia, micturition frequency, pain renal, pain urinary tract, polyuria, priapism, renal calculus, urinary tract infection.
Other: Systemic lupus erythematosus.
Postmarketing And Other Experience
The following adverse reactions have been observed in named patient programs or post-marketing experience with immediate-release Oxigrex or Oxigrex®. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Body as a Whole: multi-organ hypersensitivity disorders characterized by features such as rash, fever, lymphadenopathy, abnormal liver function tests, eosinophilia and arthralgia
Anaphylaxis:
Digestive System: pancreatitis and/or lipase and/or amylase increase
Hematologic and Lymphatic Systems: aplastic anemia
Metabolism: hypothyroidism
Skin and subcutaneous tissue disorders: erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, Acute Generalized Exanthematous Pustulosis (AGEP)
Musculoskeletal, connective tissue and bone disorders: There have been reports of decreased bone mineral density, osteoporosis and fractures in patients on long-term therapy with immediate-release Oxigrex.
Oxigrex contraindications
See also:
What is the most important information I should know about Oxigrex?
You should not take this medication if you are allergic to Oxigrex.
Before you take Oxigrex, tell your doctor if you have liver or kidney disease.
Oxigrex can make birth control pills less effective. Ask your doctor about using a non hormone method of birth control (such as a condom, diaphragm, spermicide) to prevent pregnancy while taking Oxigrex.
Oxigrex can reduce the sodium in your body to dangerously low levels, which can cause a life-threatening electrolyte imbalance. Contact your doctor right away if you have headache, problems with thinking or memory, weakness, loss of appetite, feeling unsteady, confusion, hallucinations, fainting, shallow breathing, and/or increased or more severe seizures.
You may have thoughts about suicide when you first start taking this medicine. Your doctor will need to check you at regular visits.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, depression, anxiety, or if you feel agitated, hostile, restless, hyperactive (mentally or physically), or have thoughts about suicide or hurting yourself.
There are many other medicines that can interact with Oxigrex. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor. Keep a list of all your medicines and show it to any healthcare provider who treats you.
Active ingredient matches for Oxigrex:
Oxcarbazepine in Egypt.
List of Oxigrex substitutes (brand and generic names) | Sort by popularity |
Unit description / dosage (Manufacturer) | Price, USD |
Oxicodal (Chile, Colombia, Peru) | |
Tablets; Oral; Oxcarbazepine 600 mg (Drugtech) | |
Oxilepsi (Turkey) | |
Oxileptin (India) | |
Oxileptin 300 mg Tablet (Pfizer Limited (Pharmacia India Pvt Ltd)) | $ 0.09 |
Oxileptin 150 mg Tablet (Pfizer Limited (Pharmacia India Pvt Ltd)) | $ 0.05 |
OXILEPTIN film-coated tab 150 mg x 10's (Pfizer Limited (Pharmacia India Pvt Ltd)) | $ 0.51 |
OXILEPTIN film-coated tab 300 mg x 10's (Pfizer Limited (Pharmacia India Pvt Ltd)) | $ 0.90 |
Oxital | |
Oxital 450 mg Tablet (Talent Healthcare) | $ 0.09 |
Oxital 150 mg Tablet (Talent Healthcare) | $ 0.04 |
Oxital 600 mg Tablet (Talent Healthcare) | $ 0.11 |
Oxital 300 mg Tablet (Talent Healthcare) | $ 0.06 |
Oxkarbazepin Mylan (Czech Republic) | |
OXMAZETOL | |
Oxmazetol 150mg Tablet (Abbott India Ltd) | $ 0.05 |
Oxmazetol 300mg Tablet (Abbott India Ltd) | $ 0.10 |
Oxmazetol 300mg Tablet ER (Abbott India Ltd) | $ 0.11 |
Oxmazetol 450mg Tablet (Abbott India Ltd) | $ 0.16 |
Oxmazetol 600mg Tablet (Abbott India Ltd) | $ 0.19 |
Oxmazetol 150mg Tablet SR (Abbott India Ltd) | $ 0.06 |
Oxmazetol 600mg Tablet SR (Abbott India Ltd) | $ 0.20 |
Oxmazetol SR | |
Oxmazetol SR 600 mg Tablet (Piramal Healthcare) | $ 0.14 |
Oxmazetol SR 300 mg Tablet (Piramal Healthcare) | $ 0.08 |
Oxmazetol SR 150 mg Tablet (Piramal Healthcare) | $ 0.04 |
Oxmazetol-ER (India) | |
OXMAZETOL-ER modified-release tab 150 mg x 10's (AHPL) | $ 0.46 |
OXMAZETOL-ER modified-release tab 300 mg x 10's (AHPL) | $ 0.82 |
OXMAZETOL-ER modified-release tab 600 mg x 10's (AHPL) | $ 1.40 |
Oxmazetol-SR (India) | |
Oxmazetol-SR 150mg SR-TAB / 10 | $ 0.41 |
Oxmazetol-SR 300mg SR-TAB / 10 | $ 0.76 |
Oxmazetol-SR 600mg SR-TAB / 10 | $ 1.39 |
150 mg x 10's | $ 0.41 |
300 mg x 10's | $ 0.76 |
600 mg x 10's | $ 1.39 |
Oxolon Pharma Investi (Paraguay) | |
Oxpine (India) | |
Oxpine 150mg TAB / 8x8 (Jpee Drugs) | $ 2.31 |
Oxpine 500mg TAB / 8x8 (Jpee Drugs) | $ 5.40 |
Oxpine 500 mg Tablet (Jpee Drugs) | $ 0.08 |
Oxpine 150 mg Tablet (Jpee Drugs) | $ 0.04 |
OXPINE tab 150 mg x 10's (Jpee Drugs) | $ 0.60 |
OXPINE tab 300 mg x 10's (Jpee Drugs) | $ 1.02 |
Oxrate (India) | |
OXRATE Capsule/ Tablet / 150mg / 10 units (Merind Ltd (Wockhardt Ltd)) | $ 0.36 |
OXRATE Capsule/ Tablet / 600mg / 10 units (Merind Ltd (Wockhardt Ltd)) | $ 1.18 |
OXRATE Capsule/ Tablet / 300mg / 10 units (Merind Ltd (Wockhardt Ltd)) | $ 0.66 |
Oxrate 150mg TAB / 10 (Merind Ltd (Wockhardt Ltd)) | $ 0.33 |
Oxrate 300mg TAB / 10 (Merind Ltd (Wockhardt Ltd)) | $ 0.59 |
See 978 substitutes for Oxigrex |
References
- DailyMed. "OXCARBAZEPINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "OXCARBAZEPINE". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "OXCARBAZEPINE". http://www.drugbank.ca/drugs/DB00776 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Oxigrex are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Oxigrex. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
1 consumer reported useful
Was the Oxigrex drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
Users | % | ||
---|---|---|---|
Useful | 1 | 100.0% |
Consumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology